Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer

Summary

This phase II trial is studying how well RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) works in treating patients with previously treated metastatic pancreatic cancer. RO4929097 may stop the growth of tumor cells by blocking some enzymes needed for cell growth.

Timeline

Start

2010-10

Primary completion

2012-07

Completion

2014-05

Drugs

Indications